ClinicalTrials.gg
CompletedNCT05795153Updated Oct 16, 2025Results posted

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

A Phase 3 interventional study of LOU064 in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Completed at 44 sites in 10 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
9th of 12
144 · median 347
Started
2023
with 2 others
Phase 3
9 of 12
1 open now
Registered
8th of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 9th largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 8th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

The purpose of this study was to assess the effect of remibrutinib 25 mg twice a day (b.i.d.) open-label on Systolic Blood Pressure (SBP) measured as a change in 24-hour weighted average SBP from baseline to Week 4 assessed by Ambulator Blood Pressure Monitoring (ABPM); and to assess overall safety and efficacy over 12 weeks in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled with second generation H1 antihistamines (H1-AH) treatment. ABPM was chosen for the blood pressure assessment in this trial as recommended by the FDA for drugs intended for chronic use (Assessment of Pressor Effects of Drugs Guidance for Industry (FDA 2022)).

Read the detailed description

This study consisted of a screening period of up to 4 weeks, a 12-week open-label treatment period and a treatment-free follow-up period of 4 weeks, with a total study duration of up to 20 weeks.

At the end of the treatment phase, participants had the option to continue in an extension study (CLOU064A2303B (NCT05513001)) if approved in the country and at the site.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • Chronic Spontaneous Urticaria (CSU)
  • remibrutinib
  • Systolic Blood Pressure (SBP)
  • Diastolic Blood Pressure (DBP)
  • Ambulator Blood Pressure Monitoring (ABPM)
  • H1 antihistamines (H1-AH) treatment
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed obtained prior to participation in the study
  • Male and female adult participants >= 18 years of age
  • CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the Investigator based on all available supporting documentation).
  • Diagnosis of CSU inadequately controlled by second generation H1-AH at the time of baseline (Day 1)
  • Documentation of hives within three months before baseline (either at screening and/or at baseline (Day 1); or documented in the participants' medical history).
  • Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the protocol
  • Participants had no more than 2 missing UPDD entries (either morning or evening) in the 7 days prior to baseline (Day 1).

Key Exclusion Criteria:

  • Participants unable to tolerate 24-hour ambulatory blood pressure measurement using automatic ABPM device
  • Ongoing or past history of hypertension and/or SBP >= 140 or =\< 90 OR DBP >= 90 or =\< 60 mmHg at screening
  • Participants working night shifts
  • Participants taking/requiring medications prohibited by the protocol (including those known to interfere with blood pressure assessments in the study)
  • Evidence of cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the Investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    LOU064 (remibrutinib)

    All participants were assigned to remibrutinib 25 mg b.i.d. for 12 weeks.

    Drug: LOU064

Interventions

  • DrugLOU064

    One film-coated tablet (25 mg) was to be taken in the morning and evening, respectively, with a 12-hour interval at approximately the same time everyday.

    Also known as: remibrutinib

06

What researchers measure

Primary outcomes

  1. Estimated Mean Change From Baseline at Week 4 in 24-hour Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)

    A linear regression with SBP as a covariate was employed. The change in SBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline in the 24-hour weighted average SBP was calculated using the time weighted average of the area under the curve (AUC) of SBP obtained over a 24-hour period as measured by ABPM. That is, the time weighted average of AUC of 24-hour SBP obtained at baseline was subtracted from corresponding time weighted average of AUC of SBP at Week 4. In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour SBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The Mixed Models for Repeated Measures (MMRM) approach was used.

    Time frame: Baseline, Week 4

Secondary outcomes

  1. Observed Mean Change From Baseline to Week 4 in 24-hour Weighted Average Systolic Blood Pressure (SBP) Measured by ABPM

    The change from baseline in the 24-hour weighted average systolic blood pressure (SBP) was calculated using the time weighted average of the area under the curve (AUC) of SBP obtained over a 24-hour period as measured by ABPM. This analysis was conducted using the observed data. Data was computed taking weighted averages over time and discarding time intervals of more than 1 hour without measurements.

    Time frame: Baseline, Week 4

  2. Estimated Mean Change From Baseline at Week 4 in 24-hour Diastolic Blood Pressure (DBP) Measured by ABPM

    A linear regression with DBP as a covariate was employed. The change in DBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline in the 24-hour weighted average DBP was calculated using the time weighted average of the area under the curve (AUC) of DBP obtained over a 24-hour period as measured by ABPM. That is, the time weighted average of AUC of 24-hour DBP obtained at baseline was subtracted from corresponding time weighted average of AUC of DBP at Week 4. In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour DBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The Mixed Models for Repeated Measures (MMRM) approach was used.

    Time frame: Baseline, Week 4

  3. Estimated Mean Change From Baseline at Week 4 in Daytime and Nighttime Average SBP Measured by ABPM

    The change in daytime (respectively nighttime) weighted average SBP was analyzed using linear regression model with baseline weighted average daytime SBP (respectively nighttime) as a covariate. The change in daytime (respectively nighttime) SBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline of daytime (respectively nighttime) SBP was calculated using the time weighted average of the AUC of DBP obtained over daytime (respectively nighttime) In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour SBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The multiple imputation approach was used. Daytime: from 7am until 10 pm. Nighttime: from 10pm until 7 am.

    Time frame: Baseline, Week 4

  4. Estimated Mean Change From Baseline at Week 4 in Daytime and Nighttime Average DBP Measured by ABPM

    The change in daytime (respectively nighttime) weighted average DBP was analyzed using linear regression model with baseline weighted average daytime DBP (respectively nighttime) as a covariate. The change in daytime (respectively nighttime) DBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline of daytime (respectively nighttime) DBP was calculated using the time weighted average of the AUC of DBP obtained over daytime (respectively nighttime) In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour DBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The multiple imputation approach was used. Daytime: from 7am until 10 pm. Nighttime: from 10pm until 7 am.

    Time frame: Baseline, Week 4

07

Results

Posted Apr 30, 2025

Participant flow

This study was conducted globally across 10 countries: Argentina (4 centers), Canada (2 centers), France (8 centers), Germany (6 centers), Republic of Korea (3 centers), Singapore (1 center), Slovakia (3 centers), Spain (4 centers), Turkey (3 centers), and USA (11 centers).

Participant flow — Overall Study
MilestoneLOU064 (Remibrutinib)
Started144
Completed137
Not completed7
Withdrew: Adverse event2
Withdrew: Unsatisfactory therapeutic effect2
Withdrew: Lost to follow-up1
Withdrew: Subject decision2

Outcome measures

PrimaryEstimated Mean Change From Baseline at Week 4 in 24-hour Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)

A linear regression with SBP as a covariate was employed. The change in SBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline in the 24-hour weighted average SBP was calculated using the time weighted average of the area under the curve (AUC) of SBP obtained over a 24-hour period as measured by ABPM. That is, the time weighted average of AUC of 24-hour SBP obtained at baseline was subtracted from corresponding time weighted average of AUC of SBP at Week 4. In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour SBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The Mixed Models for Repeated Measures (MMRM) approach was used.

Time frame:
Baseline, Week 4
Reported as:
Mean · millimeter of mercury (mmHg)
Estimated Mean Change From Baseline at Week 4 in 24-hour Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)
millimeter of mercury (mmHg)LOU064 (Remibrutinib)
Estimated Mean Change From Baseline at Week 4 in 24-hour Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)-1.3 (-2.3 to -0.3)
SecondaryObserved Mean Change From Baseline to Week 4 in 24-hour Weighted Average Systolic Blood Pressure (SBP) Measured by ABPM

The change from baseline in the 24-hour weighted average systolic blood pressure (SBP) was calculated using the time weighted average of the area under the curve (AUC) of SBP obtained over a 24-hour period as measured by ABPM. This analysis was conducted using the observed data. Data was computed taking weighted averages over time and discarding time intervals of more than 1 hour without measurements.

Time frame:
Baseline, Week 4
Reported as:
Mean · millimeter of mercury (mmHg)
Observed Mean Change From Baseline to Week 4 in 24-hour Weighted Average Systolic Blood Pressure (SBP) Measured by ABPM
millimeter of mercury (mmHg)LOU064 (Remibrutinib)
Observed Mean Change From Baseline to Week 4 in 24-hour Weighted Average Systolic Blood Pressure (SBP) Measured by ABPM-1.65 ± 6.905
SecondaryEstimated Mean Change From Baseline at Week 4 in 24-hour Diastolic Blood Pressure (DBP) Measured by ABPM

A linear regression with DBP as a covariate was employed. The change in DBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline in the 24-hour weighted average DBP was calculated using the time weighted average of the area under the curve (AUC) of DBP obtained over a 24-hour period as measured by ABPM. That is, the time weighted average of AUC of 24-hour DBP obtained at baseline was subtracted from corresponding time weighted average of AUC of DBP at Week 4. In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour DBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The Mixed Models for Repeated Measures (MMRM) approach was used.

Time frame:
Baseline, Week 4
Reported as:
Mean · millimeter of mercury (mmHg)
Estimated Mean Change From Baseline at Week 4 in 24-hour Diastolic Blood Pressure (DBP) Measured by ABPM
millimeter of mercury (mmHg)LOU064 (Remibrutinib)
Estimated Mean Change From Baseline at Week 4 in 24-hour Diastolic Blood Pressure (DBP) Measured by ABPM-0.1 (-0.8 to 0.6)
SecondaryEstimated Mean Change From Baseline at Week 4 in Daytime and Nighttime Average SBP Measured by ABPM

The change in daytime (respectively nighttime) weighted average SBP was analyzed using linear regression model with baseline weighted average daytime SBP (respectively nighttime) as a covariate. The change in daytime (respectively nighttime) SBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline of daytime (respectively nighttime) SBP was calculated using the time weighted average of the AUC of DBP obtained over daytime (respectively nighttime) In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour SBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The multiple imputation approach was used. Daytime: from 7am until 10 pm. Nighttime: from 10pm until 7 am.

Time frame:
Baseline, Week 4
Reported as:
Mean · millimeter of mercury (mmHg)
Estimated Mean Change From Baseline at Week 4 in Daytime and Nighttime Average SBP Measured by ABPM
millimeter of mercury (mmHg)LOU064 (Remibrutinib)
daytime average SBP-1.2 (-2.3 to -0.0)
nighttime average SBP-0.9 (-2.2 to 0.5)
SecondaryEstimated Mean Change From Baseline at Week 4 in Daytime and Nighttime Average DBP Measured by ABPM

The change in daytime (respectively nighttime) weighted average DBP was analyzed using linear regression model with baseline weighted average daytime DBP (respectively nighttime) as a covariate. The change in daytime (respectively nighttime) DBP from baseline to Week 4 was predicted at the median baseline level. The change from baseline of daytime (respectively nighttime) DBP was calculated using the time weighted average of the AUC of DBP obtained over daytime (respectively nighttime) In the analysis, if participants took prohibited antihypertensive treatment before Week 4, their subsequent measurements were excluded. In such cases, the excluded measurements were imputed by increasing the 24-hour DBP by 3 mmHg from the baseline value at Week 4. Moreover, participants who discontinued of study treatment due to any reason prior to the Week 4 were excluded from the analysis. The multiple imputation approach was used. Daytime: from 7am until 10 pm. Nighttime: from 10pm until 7 am.

Time frame:
Baseline, Week 4
Reported as:
Mean · millimeter of mercury (mmHg)
Estimated Mean Change From Baseline at Week 4 in Daytime and Nighttime Average DBP Measured by ABPM
millimeter of mercury (mmHg)LOU064 (Remibrutinib)
daytime average DBP-0.6 (-1.3 to 0.2)
nighttime average DBP0.2 (-0.8 to 1.1)

Adverse events

Collected over On-treatment adverse events and deaths were reported from first dose of study medication up to 28 days after last dose of study medication, assessed up to approximately 18 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LOU064 (Remibrutinib)0/144 (0%)4/144 (2.8%)32/144 (22.2%)
Most frequent serious events
Most frequent serious events
EventLOU064 (Remibrutinib)
Cholecystitis acuteHepatobiliary disorders1/144
DizzinessNervous system disorders1/144
Chronic spontaneous urticariaSkin and subcutaneous tissue disorders1/144
Aortic dissectionVascular disorders1/144
Most frequent other events
Most frequent other events
EventLOU064 (Remibrutinib)
HeadacheNervous system disorders13/144
NasopharyngitisInfections and infestations12/144
Chronic spontaneous urticariaSkin and subcutaneous tissue disorders8/144

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LOU064 (Remibrutinib)
Mean42.2 ± 14.52
Sex: Female, Male
Sex: Female, Male(Participants)LOU064 (Remibrutinib)
Female105
Male39
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LOU064 (Remibrutinib)
American Indian or Alaska Native1
Asian19
Native Hawaiian or Other Pacific Islander0
Black or African American3
White89
More than one race0
Unknown or Not Reported32
Baseline Systolic Blood Pressure (SBP)
Baseline Systolic Blood Pressure (SBP)(millimeter of mercury (mmHg))LOU064 (Remibrutinib)
Mean117.1 ± 13.11
Baseline Diastolic Blood Pressure (DBP)
Baseline Diastolic Blood Pressure (DBP)(millimeter of mercury (mmHg))LOU064 (Remibrutinib)
Mean75.0 ± 8.98
08

Study locations

44 sites
  • Acuro Research Inc
    Little Rock, Arkansas 72205, United States
  • Florida Ctr Allergy Asthma Research
    Aventura, Florida 33180, United States
  • Finlay Medical Research
    Greenacres City, Florida 33467, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Endeavor Health
    Glenview, Illinois 60077, United States
  • Allergy and Asthma Specialist P S C
    Owensboro, Kentucky 42301, United States
  • Allergy Asthma and Clinical Research
    Oklahoma City, Oklahoma 73120, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • Western Sky Medical Research
    El Paso, Texas 79924, United States
  • Allergy Asthma and amp Sinus Ctr S C
    Greenfield, Wisconsin 53228, United States
  • Novartis Investigative Site
    Nueve de Julio, Buenos Aires B6500BWQ, Argentina
  • Novartis Investigative Site
    Sourigues, Buenos Aires B1837, Argentina
  • Novartis Investigative Site
    Santa Fe, Rosario S2000DBS, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000JKR, Argentina
  • Novartis Investigative Site
    Calgary, Alberta T2M 1A6, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2V 2K1, Canada
  • Novartis Investigative Site
    Angers, 49933, France
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75970, France
  • Novartis Investigative Site
    Reims, 51100, France
  • Novartis Investigative Site
    Saint-Mandé, 94160, France
  • Novartis Investigative Site
    Toulouse, 31400, France
  • Novartis Investigative Site
    Bramsche, Lower Saxony 49565, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06108, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Hanover, 30625, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Singapore, 308205, Singapore
  • Novartis Investigative Site
    Komárno, 945 01, Slovakia
  • Novartis Investigative Site
    Levice, 934 01, Slovakia
  • Novartis Investigative Site
    Nové Zámky, 940 34, Slovakia
  • Novartis Investigative Site
    Daegu, Dalseo Gu 41931, South Korea
  • Novartis Investigative Site
    Suwon, Gyeonggi-do 16499, South Korea
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Alicante, Valencia 03010, Spain
  • Novartis Investigative Site
    Valencia, Valencia 46014, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Izmir, 35140, Turkey (Türkiye)
  • Novartis Investigative Site
    Kayseri, 38070, Turkey (Türkiye)
  • Novartis Investigative Site
    Samsun, 55139, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Apr 2024, 12 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 3, 2023
StartActual
Apr 5, 2023
Primary completionActual
Apr 25, 2024
CompletionActual
Apr 25, 2024
Results first posted
Apr 30, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05795153
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Apr 5, 2023
Primary completion
Apr 25, 2024
Completion
Apr 25, 2024
Results posted
Apr 30, 2025
Last update
Oct 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion